 LEXINGTON, Mass., March 23, 2021 GLOBE NEWSWIRE -- Translate Bio Nasdaq: TBIO, a clinical-stage messenger RNA mRNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on March 22, 2021, the Company granted non-qualified stock options to purchase an aggregate of 300,000 shares of the Companys common stock to its newly hired President, Dr. Rand Sutherland. This grant was made pursuant to the Companys 2021 Inducement Stock Incentive Plan, was approved by the Companys board of directors, and was made as a material inducement to Dr. Sutherlands acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635c4 as a component of his employment compensation. 